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Abstract 
Purpose: To explore the effects of Prunella vulgaris L extract (PVE) on hyperplasia of mammary gland 
(HMG) in rats.  
Methods: Forty virgin female Wistar rats were randomly divided into normal group, control group (HMG 
model), positive control group (Rupixiao Capsule, RPXC), and low-, medium- and high-dose (150, 300 
and 600 mg/kg) of PVE groups. Injections of estrogen and progestogen were given at the same time to 
prepare rat. Changes in nipple height were measured, while serum estradiol (E2), progesterone (P), 
prolactin (PRL), follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels were evaluated 
by ELISA; Uterus and ovary indices were determined.  
Results: Compared with control group, PVE reduced elevated nipple height to 2.25 ± 0.09 mm (p < 
0.01) and uterus index to 2.29 ± 0.41 mg/g (p < 0.01), as well as reduced the number of mammary 
gland lobules and secretion in HMG rats. Compared with control group, serum E2 (2.81 ± 0.17 pmol/L), 
PRL (269.38 ± 8.28 pg/mL) and FSH (0.13 ± 0.03 IU/L) levels (p < 0.01) were lowered, but serum P 
(1.31 ± 0.13 ng/mL) and LH (1.73 ± 0.08 mIU/mL) levels were higher (p < 0.01) in rats treated with high-
dose PVE.  
Conclusion: These results suggest that PVE exerts anti-HMG effect in rats induced by estrogen and 
progestogen. 
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Hyperplasia of mammary gland (HMG) is a 
common disease in middle-aged women. It is a 
kind of pathological hyperplasia of lobules of 
mammary gland induced by balance disorder of 
estrogen and progesterone. The morbidity of 
HMG is increasing nowadays, with a risk of 
causing mammary carcinoma. Therefore, it is 
important to search for more convenient and 
effective new drugs with few side effects for 
treating hyperplasia of mammary glands as well 
as explore the anti-HMG mechanisms of these 
drugs that would block its development into 
breast cancer [1].  
 
HMG is related to menstrual cycle, breast-
feeding, occupation, abuse of sex hormone 
drugs, diet and stress [2,3]. HMG patients have 
increased in number in recent years. Studies 
have shown that some Traditional Chinese 
Medicine products may improve regulatory 
mechanisms of the body that could inhibit HMG 
[4]. 
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Prunella vulgaris L, is a herb from barley that is 
widely used in China. It is capable of regulating 
endocrine disorder and is frequently used in the 
treatment of HMG [5]. The aim of the present 
study was to examine the therapeutic effect of 
Prunella vulgaris L extract against hyperplasia of 






The herbal samples of were collected from 
Luoyang City, Henan Province in China in May 
2015. Taxonomic identification of the plant was 
performed by Professor Lu Gan of Zhejiang 
University, in China. A voucher specimen of 
herbarium (no. PVE 201505027) was deposited 
in the herbarium of College of Pharmacy, 
Zhejiang University, China for future reference. 
The aqueous extract of Prunella vulgaris L was 
obtained by steeping the dried Prunella vulgaris 
L in water at 60 oC three times, for 1 hour on 
each occasion. Then it was dried in a oven and 





Virgin female Wistar rats weighing 200 – 240 g 
and Kunming female mice (18 - 22g) were 
provided by the Experimental Animal Center of 
Zhejiang Province (Certificate no. SYXK 2005-
0002). The animals had free access to food and 
water, and were allowed to acclimatize for at 
least one week before use. The rat experiment 
was approved by Animal Care and Use 
Committee of Ningbo No. 9 Hospital (approval ref 
no. 20110605) and was carried out in compliance 
with Directive 2010/63/EU on the handling of 
animals used for scientific purposes [6]. 
 
Animal groups  
 
Rats were treated with estrogen (0.5 mg/kg) 
intra-muscularly for 25 days, followed by 
progestogen (5 mg/kg) for another 5 days to 
induce HMG model. The rats were randomly 
divided into 6 groups of ten rats: normal group, 
model group, positive group (Rupixiao Capsule, 
RPXC 400 mg/kg) as well as PVE groups (150, 
300 and 600 mg/kg doses). From the 31st day, 
the rats in the normal group and model group 
received distilled water by gavage, the rats in 
RPXC group were treated with RPXC, and the 
rats in the PVE group were respectively 
administered PVE by intragastric administration. 
Treatments were given orally once daily for 4 
weeks. 
 
Cotton pellet-induced granuloma  
 
Sterile cotton pellets (10 mg) were implanted 
subcutaneously in groin of anesthetized mice (18 
– 22 g). Ten animals were used for every 
treatment. The animals received 150, 300 and 
600 mg/kg of PVE, RPXC (400 mg/kg) or saline 
(10 ml/kg) orally, once a day through an oral 
cannula over 7 consecutive days. On the 8th 
day, the mice were sacrificed and the cotton 
pellet removed, dried overnight at 60 °C and 
weighed. The increase in weight of cotton pellet 
was determined and used for further calculation. 
 
Determination of nipple height and 
biochemical assay 
 
The nipple height of all rats were measured after 
the treatment. The contents of sex hormones - 
E2, P, PRL, FSH and LH - were determined 
using ELISA kits (Nanjing Jiancheng Co Ltd, 
China). Uterus index was calculated as uterus 
weight divided by body weight, while ovary index 





Values are expressed as mean ± SEM. Multiple 
group comparisons were performed using one-
way analysis of variance (ANOVA) followed by 
Dunnett’s test to detect intergroup differences. P 





Cotton pellet-induced granuloma 
 
The results revealed that PVE significantly 
inhibited the dried weight of the cotton pellet 
granuloma in a dose-dependent manner. The 
values for doses of 150, 300 and 600 mg/kg 
PVE were 18.15, 22.24 and 28.14 %, 
respectively. RPXC inhibited granuloma tissue 
formation by 17.21 %, which is lower than that 
observed for 100 mg/kg dose of PVE. Thus, 
PVE significantly suppressed granulomatous 
tissue formation during chronic inflammation 
(Table 1). 
 
Effect of PVE on rat nipple height  
 
The height of nipples (right 2 and right 3) of rats 
was significantly decreased by RPXC (400 
mg/kg) and PVE (600 mg/kg) treatments 
compared with HMG control group (p < 0.01, 
Table 2). 
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(mg) Inhibition rate (%) P-value 
Normal — 72.36 ± 8.41   
RPXC 400 64.24 ± 11.56 16.68 > 0.05 
PVE-L  150 62.12 ± 15.78 19.26 > 0.05 
PVE-M 300 57.28 ± 13.35 24.35 < 0.05 
PVE-H  600 55.76 ± 12.29 27.29 < 0.05 
*P < 0.05 **p < 0.01 vs model group; PVE-L: low-dose of PVE; PVE-M: middle-dose of PVE; PVE-H: high-dose 
of PVE; RPXC: Rupixiao Capsule 
 
       Table 2: Effect of PVE on nipple height in rats 
 
Group Dosage Nipple height (mm) 
 (mg/kg)  Right 2 Right 3 
Normal — 1.62 ± 0.15** 1.63 ± 0.16** 
Control — 2.79 ± 0.27 2.64 ± 0.21 
RPXC 400 2.24 ± 0.23** 2.34 ± 0.12** 
PVE-H  600 1.93 ± 0.08** 2.25 ± 0.09** 
*P < 0.05 **p < 0.01 vs model group; PVE-H: high-dose of PVE; RPXC: Rupixiao Capsule 
 
Table 3: Effect of PVE on serum sex hormone levels in rats 
 
Group Dosage (mg/kg)  E2 (pmol/L) P (ng/mL) PRL (pg/mL) FSH (IU/L) LH (mIU/mL) 
Normal — 2.85±0.38** 1.45±0.17** 275.46±6.48** 0.12±0.02*  1.92±0.09* 
Model — 4.65±0.16 0.72±0.08 398.54±8.26 0.58±0.02 1.12±0.05 
RPXC 400 3.36±0.24* 1.22±0.15* 423.23±12.34 0.47±0.19 1.42±0.10* 
PVE-H 600 2.81±0.17** 1.31±0.13** 269.38±8.28** 0.13±0.03** 1.73±0.08* 
*P < 0.05 **p < 0.01 vs. model group; PVE-H: high-dose of PVE; RPXC: Rupixiao Capsule 
 
Effect of PVE on rat serum sex hormone 
levels  
 
After injection of estrogen and progestogen, E2, 
PRL and FSH contents were significantly 
increased, while P and LH levels decreased in 
HMG control rats. E2, PRL and FSH were 
decreased by PVE (600 mg/kg) treatment 
compared with model group (p < 0.01), P and LH 
contents was remarkably increased compared to 
HMG control group (p < 0.01) (Table 3). 
 
Effect of PVE on uterus and ovary index in 
rats 
 
Uterus index in HMG model rats were 
significantly increased compared with normal 
group (p < 0.01). Uterus index was significantly 
decreased by RPXC (400 mg/kg) (p < 0.01) and 
PVE (600 mg/kg) (p < 0.05) treatment as 
compared with HMG model group. Ovary index 
was not shown distinct difference compared with 




There is evidence that chronic inflammation 
brought about by persistent chemical, bacterial or 
viral agents is a risk factor for cancer [7-10]. 
Inflammation by innate immunity, which is 
required to fight microbial infections, heal 
wounds and maintain tissue homeostasis, can 
lead to cancer [11-13]. 
 








Normal — 2.23 ± 0.36** 0.82 ± 0.08 
Model — 2.87 ± 0.41 0.52 ± 0.12 
RPXC 400 2.35 ± 0.24** 0.47 ± 0.06 
PVE-H 600 2.29 ± 0.41* 0.45 ± 0.06 
*P < 0.05 **p < 0.01 vs model group; PVE-H: high-
dose of PVE; RPXC: Rupixiao Capsule 
 
Several recent studies have suggested that 
inflammation has an important role in all phases 
of tumor development, including tumor initiation, 
tumor promotion, invasion, metastatic 
dissemination, and evasion of immune system 
[14]. The development of many types of cancer 
including breast cancer is related to 
inflammation.  
 
Epidemiological studies have revealed that the 
use of non-steroidal anti-inflammatory drugs can 
decrease the risk of developing breast cancer 
[15,16]. The study revealed that PVE-H had 
strong anti-inflammatory activities in chronic 
inflammation model mice. The inflammatory 
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granuloma is a typical feature of a chronic 
inflammatory process. The dried weight of the 
pellets correlates with the amount of 
granulomatous tissue. Therefore, cotton pellet 
granuloma method has been widely used to 
evaluate the proliferative components of chronic 
inflammation. 
 
In the present study, PVE inhibited chronic 
proliferative inflammation processes with a dose-
dependent inhibition of granuloma formation in 
mice, and also has ameliorative effects in HMG 
rats induced by estrogen and progestogen. The 
heights of nipples of rats were significantly 
decreased by PVE-H treatment compared with 
control. Results showed that uterus index were 
remarkably decreased by PVE-H treatment 
compared with HMG model group. Ovary index 
was not shown distinct difference compared with 
control group. After administration of PVE-H in 
HMG rats, E2, PRL and FSH were remarkably 
decreased, while P and LH significantly 




The findings of this study demonstrate that PVE 
significantly inhibits mammary gland hyperplasia 
in rats. Therefore, the plant has the potential to 
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